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Abstract
Background: The receptor tyrosine kinase like orphan receptor (ROR)-1 gene is overexpressed in chronic lymphocytic
leukemia (CLL). Because Stat3 is constitutively activated in CLL and sequence analysis revealed that the ROR1 promoter
harbors c-interferon activation sequence-like elements typically activated by Stat3, we hypothesized that Stat3 activates
ROR1.
Methodology/Principal Findings: Because IL-6 induced Stat3 phosphorylation and upregulated Ror1 protein levels in MM1
cells, we used these cells as a model. We transfected MM1 cells with truncated ROR1 promoter luciferase reporter constructs
and found that IL-6 induced luciferase activity of ROR1-195 and upstream constructs. Co-transfection with Stat3 siRNA
reduced the IL-6-induced luciferase activity, suggesting that IL-6 induced luciferase activity by activating Stat3. EMSA and
the ChIP assay confirmed that Stat3 binds ROR1, and EMSA studies identified two Stat3 binding sites. In CLL cells, EMSA and
ChIP studies determined that phosphorylated Stat3 bound to the ROR1 promoter at those two ROR1 promoter sites, and
ChIP analysis showed that Stat3 co-immunoprecipitated DNA of STAT3, ROR1, and several Stat3-regulated genes. Finally,
like STAT3-siRNA in MM1 cells, STAT3-shRNA downregulated STAT3, ROR1, and STAT3-regulated genes and Stat3 and Ror1
protein levels in CLL cells.
Conclusion/Significance: Our data suggest that constitutively activated Stat3 binds to the ROR1 promoter and activates
ROR1 in CLL cells.
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Introduction
Receptor tyrosine kinase like orphan (Ror) proteins are type-I
transmembrane receptor tyrosine kinase members of the neuro-
trophic tyrosine kinase receptor superfamily that regulate the
developmental wingless-type (Wnt) signaling pathway [1]. The
extracellular region of Ror proteins contains an immunoglobulin
domain, a Cys-rich domain, also called the Frizzled domain, and a
Kringle domain. Intracellularly, Ror proteins possess a tyrosine
kinase domain and a proline-rich domain straddled by two Ser/
Thr-rich domains [2]. The vertebrate ROR family members,
ROR1 and ROR2, were first identified in a human neuroblas-
toma cell line by a polymerase chain reaction (PCR)-based search
for tyrosine kinases [2]. In humans, Ror protein functions are
involved in skeletal development. Human ROR2 mutations cause
well-characterized skeletal defects such as dominant brachydactily
type B, a condition of shortened or missing digits [3,4], and
recessive Robinow syndrome, a form of short-limbed dwarfism
[5,6]. Human ROR2 polymorphisms are also associated with
variations in bone length and mineral density [7]. Similar to
ROR2, human ROR1 plays a role in embryonic organogenesis.
However, unlike ROR2, mutations in human ROR1 have not
been linked to any human disease thus far.
ROR1, however, is overexpressed in B-cell chronic lymphocytic
leukemia (CLL) cells. Unlike normal granulocytes, B-, or T-cells,
leukemia cells from all patients with CLL spontaneously express
ROR1 mRNA [8,9,10]. Protein analysis has revealed that CLL
blood lymphocytes, but not normal resting B-lymphocytes, express
two different variants of the Ror1 protein, 105 kd and 130 kd [8].
Cell-surface Ror1 has been detected in CLL cells by flow
cytometry, western immunoblotting, and ELISA [10]. Anti-Ror1
monoclonal antibodies were found to react with CLL cells, but not
with a variety of normal adult tissues, nonleukemic leukocytes, or
blood mononuclear cells, including CD5+ B cells of healthy adults
[11].
B-cell CLL, the most common adult leukemia in the Western
hemisphere, is characterized by the accumulation of neoplastic B-
lymphocytes co-expressing CD5 and CD19 antigens [12]. Unlike
in other hematologic malignancies, in CLL Stat3 is constitutively
phosphorylated exclusively on serine 727 residues [13], translo-
cates to the nucleus, binds to DNA, and activates the transcription
of genes known to be transcribed by tyrosine-phosphorylated Stat3
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activation sequence (GAS)-like element, also referred to as the sis-
inducible element, located in the promoter region of various genes
[15]. Because sequence analysis identified GAS-like elements in
the ROR1 promoter (Fig. 1), we hypothesized that Stat3 binds to
the ROR1 promoter in CLL cells.
Results
CLL cells express Ror1 protein
We first sought to confirm that Ror1 protein is present in
unstimulated CLL cells [8,10,11]. We fractionated low-density
cells from the peripheral blood (PB) of seven patients with CLL
(Table S1), and by using western immunoblotting, we detected
both the 105- and 130-Kd variants of the Ror1 protein in all
samples. As expected [13,14], we also found that Stat3 was
constitutively phosphorylated on serine 727 residues in all samples
(Fig. 2A).
IL-6 phosphorylates Stat3 and upregulates Ror1 protein
levels in MM1 cells
To test the hypothesis that Stat3 activates ROR1, we used the
multiple myeloma cell line MM1. Unstimulated MM1 cells
express low to undetectable levels of phosphotyrosine-Stat3, and
exposure of MM1 cells to IL-6 induces Stat3 phosphorylation
[16,17]. We incubated MM1 cells with IL-6 and, using western
blot analysis, found that IL-6 induced tyrosine phosphorylation of
Stat3. IL-6 also upregulated Ror1 protein levels in a dose-and
time-dependent manner, whereas both phospho-Stat3 and Ror1
were almost undetectable in untreated MM1 cells (Fig. 2B).
IL-6 induces ROR1 promoter activity in MM1 cells by
activating Stat3
In order to determine whether activated Stat3 binds to the
ROR1 promoter, we cloned the human ROR1 promoter
(1522 bp) into a luciferase reporter plasmid and generated a series
of truncated constructs (Fig. 3A, left panel). The location of the 59
regions of these constructs is underlined in Fig. 1, and the primers
used to generate them are depicted in Table S2. All constructs
were transfected into MM1 cells (transfection efficiency: 45–50%;
not shown), and their activity was assessed, after incubation with
either 20 ng/ml IL-6 or culture medium, by using the luciferase
reporter assay and the Renila system. Exposure of MM1 cells to
IL-6 significantly increased luciferase activity in ROR1 2195
(from 2195 to +349; 544 bp), ROR1 2666 (from 2666 to +349;
1015 bp), ROR1 2834 (from 2834 to +349; 1183 bp), and
ROR1 21173 (from 21173 to +349; 1522 bp). IL-6 did not
significantly increase luciferase activity in ROR1 232 (from 232
to +349; 381 bp) or ROR1 +177 (from +177 to +349; 172 bp)
(Figure 3A, right panel). Among the serial deletion clones, ROR1
21173 exerted the highest, and ROR1 232 the lowest, IL-6-
induced promoter activity (Fig. 3A).
The luciferase activity of ROR1 2195, ROR1 2360 (from
2360 to +349; 709 bp), ROR1 2666, and ROR1 2834 suggests
that the ROR1-activating elements are located upstream of
232 bp and that the region spanning between 2666 and
Figure 1. Sequence of the 59-flanking region of the human ROR1 promoter. Underlined are the primers used to generate ROR1 promoter
fragments. The putative Stat3 binding sites are shown in red. Gray denotes the exon region and ATG is the starting codon.
doi:10.1371/journal.pone.0011859.g001
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Because the region downstream of 2195 contains two GAS-like
elements, and ROR1 232 had no luciferase activity, we assumed
that STAT3 binds to a GAS-like element located at minus 133 to
2124 bp (Fig. 1). To test this assumption, a construct of 350 bp
spanning from 2360 to 210 was prepared. The luciferase activity
of this construct was almost identical to that of ROR1 21173
(Fig. 3A), confirming that this region plays a crucial role in ROR1
expression and suggesting that 2133 to 2124 bp is a Stat3
binding site.
These results, together with the data showing that IL-6 induced
Stat3 phosphorylation and upregulated Ror1 protein levels in
MM1 cells (Fig. 2B), suggest that IL-6 induces luciferase activity of
the ROR1 promoter by activating Stat3. To further delineate
these findings, MM1 cells were co-transfected with the ROR1
2195 or ROR1 2360 construct and Stat3-siRNA (co-transfection
efficiency: 46%; Fig. 3B) and incubated with IL-6. As shown in
Fig. 3C, co-transfection with Stat3-siRNA significantly downreg-
ulated the IL-6-induced luciferase activity of ROR1 2195 or
ROR1 2360, confirming that IL-6 induced luciferase activity by
activating Stat3.
Stat3 binds to the ROR1 promoter and activates ROR1 in
MM1 cells
Because we assumed that the Stat3-binding sites are located at
2133 to 2124 bp and upstream regions such as 2429 to
2400 bp (Fig. 3A, lower panel; Fig. 1), we generated four
biotinylated DNA probes, each harboring a putative Stat3 binding
site (one downstream [probe 2], and two upstream [probes 3 and
4] of the region spanning from bp 2133 to 2124 [probe 1]) and,
using these probes, we conducted an EMSA. As shown in Fig. 3D,
probes 1 and 3, but not probes 2 and 4, bound IL-6-stimulated
MM1-cell nuclear extract, and the binding of the labeled probes
was reduced by the corresponding unbiotinylated probe (Fig. 3D),
suggesting that nuclear protein binds to these sites. Indeed, a T to
G mutation either at position 2133 or position 2418 of these
putative Stat3 binding sites abrogated the IL-6-induced luciferase
activity of ROR1 2834 (Fig. 3E).
Figure 2. CLL cells constitutively express phosphoserine-Stat3 and Ror1 protein, and IL-6 upregulates phosphotyrosine-Stat3 and
Ror1 protein levels in MM1 cells. A. Western immunoblotting of unstimulated CLL cells from 7 different patients shows constitutive expression of
phosphoserine-Stat3 and both the 105- and 130-Kd variants of the Ror1 protein. B. MM1 cells were incubated for 2 hours with increasing
concentrations of IL-6. As determined by western immunoblotting, IL-6 induced Stat3 tyrosine phosphorylation and upregulated Ror1 protein levels
in a dose-dependent manner. C. MM1 cells were incubated with 20 ng/ml IL-6 and harvested at different time points for further analysis. As
determined by western immunoblotting, IL-6 induced Stat3 tyrosine phosphorylation and upregulated Ror1 protein levels in a time-dependent
manner.
doi:10.1371/journal.pone.0011859.g002
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binds to the ROR1 promoter, we conducted another EMSA
using probe 1. As shown in Fig. 4A, the biotinylated ROR1 DNA
probe bound MM1 nuclear protein, and anti-Stat3 and anti-
phosphotyrosine Stat3 antibodies attenuated the nuclear protein-
DNA binding, suggesting that activated Stat3 binds to the ROR1
promoter. To validate these findings, we conducted a ChIP
analysis of IL-6-treated and -untreated MM1 cells. As shown in
Fig. 4B, anti-Stat3 antibodies immunoprecipitated ROR1,
STAT3 (as Stat3 binds to and induces STAT3 [18]), the Stat3-
regulated gene WAF1/p21, and c-Myc promoters. A stronger
signal was obtained from chromatin of IL-6-stimulated MM1
cells. Next, we sought to determine whether Stat3 transcribes
ROR1. We transfected MM1 cells with STAT3-siRNA, stimu-
lated them with IL-6, and determined mRNA levels of ROR1,
STAT3, and various Stat3-regulated genes by using relative
qRT-PCR. As shown in Fig. 4C, STAT3-siRNA downregulated
mRNA levels of ROR1 and the Stat3-regulated genes STAT3, c-
Myc, Cyclin D1, and WAF1/p21. Furthermore, STAT3-siRNA,
but not scrambled siRNA or glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH), downregulated the Stat3 protein levels by
50% and the 130-Kd and 105-Kd Ror1 protein variant levels by
60% and 50%, respectively, suggesting that Stat3 transcribes
ROR1 and induces the production of Ror1 protein in MM1 cells
(Fig. 4D).
Serine-phosphorylated Stat3 binds the ROR1 promoter in
CLL cells
In CLL cells Stat3 is constitutively phosphorylated on serine 727
residues and activates the transcription of Stat3-regulated genes
[14]. To test whether Stat3 binds to the ROR1 promoter in CLL
cells, we used EMSA. As shown in Fig. 5A, nuclear protein from
two different patients bound to the ROR1 DNA biotinylated
probe, and the binding was partially reversed by the unbiotiny-
lated probe. Similarly, anti-Stat3 and anti-phosphoserine-Stat3
antibodies attenuated the protein-DNA binding (Fig. 5A). To
determine whether Stat3 binds to the same binding sites in CLL
cells as in MM1 cells, we used the ChIP assay. We generated five
specific primer sets for PCR analysis (Fig. 5B). Four sets were
designed to amplify promoter regions containing Stat3 putative
binding sites that we previously studied in MM1 cells (Fig. 3), and
an additional set (primer set 5) was designed to amplify a region
lacking GAS-like elements. As shown in Fig. 5C, amplification was
detected only with probes designed to amplify regions harboring
the Stat3 binding sites 1 and 3, suggesting that these two Stat3
binding sites are operative in both MM1 and CLL cells. To
confirm this observation, we conducted another ChIP study and
found that Stat3 co-immunoprecipitated the promoters of ROR1
and the Stat3-regulated genes STAT3, c-Myc, and WAF1/P21
but not of the control gene RPL30 (Fig. 5D). These data suggest
that Stat3 binds to the ROR1 promoter in CLL cells.
Stat3 transcribes ROR1 and induces Ror1 protein
production in CLL cells
We next sought to determine whether Stat3 activates ROR1 in
CLL cells. We infected CLL cells with a lentivirus harboring
STAT3-shRNA (infection efficiency: 68%; Fig. 6A) and quanti-
tated Stat3-regulated gene mRNA levels by relative qRT-PCR. As
shown in Fig. 6B, infection with STAT3-shRNA reduced the
mRNA levels of ROR1 and the Stat3-regulated genes STAT3,
Bcl2, Bcl-XL, Cyclin D1, c-Myc, WAF1/p21, and Pim1.
Furthermore, unlike empty vector, STAT3-shRNA downregulat-
ed the protein levels of Stat3 by 80% and of the 130-Kd and 105-
Kd Ror1 protein variants by 60% and 70%, respectively (Fig. 6C).
Remarkably, transfection of CLL cells with ROR1-siRNA
downregulated ROR1 mRNA and Ror1 protein levels and
induced apoptosis (Fig. 6D). Taken together, these data suggest
that in CLL cells, Stat3, constitutively phosphorylated on serine
727 residues, activates ROR1 transcription and induces Ror1
protein production.
Discussion
CLL is characterized by a dynamic imbalance between the
proliferation and apoptosis of neoplastic B-lymphocytes co-
expressing CD5 and CD19 antigens [19,20,21]. More than a
decade ago, Frank et al. reported that Stat3 is constitutively
phosophorylated on serine 727 residues in CLL cells [13].
Recently, we found that similar to tyrosine-phosphorylated Stat3
in other neoplasms, serine-phosphorylated Stat3 activates prolif-
eration and survival genes in CLL [14]. Other investigators have
reported that the Wnt signaling pathway is activated [22] and the
Wnt receptor ROR1 gene is overexpressed in CLL cells. Here, we
demonstrate that constitutively activated Stat3 binds to the ROR1
promoter, activates ROR1, and induces the production of Ror1
protein in CLL cells.
Wnt proteins are a large family of secreted glycoproteins that
activate signal transduction pathways that control proliferation,
survival, and migration. Gene expression analysis of CLL cells
showed that multiple Wnt genes are highly expressed in CLL cells
compared with normal B cells [9,22]. Different factors contribute
to Wnt gene expression in CLL. Wnt10b, transcribed by nuclear
factor (NF)-kB [23], and Wnt5a, transcribed by NF-kB and the
Notch signaling cascade [24], are both constitutively activated in
CLL [25,26]. In addition, several Wnt antagonist genes, such as
WIF1, DKK3, APC, SFRP1, SFRP2, SFRP4, and SFRP5, are
methylated and their expression downregulated in CLL cells
[27,28]. Because Wnt3 has been shown to promote the
proliferation of mouse bone marrow pro-B cells [29], it was
speculated that Wnt might stimulate CLL cell proliferation in an
autocrine manner [9]. Indeed, an analog of a non-steroidal anti-
inflammatory drug (R-etodolac) that inhibits the Wnt/b-catenin
pathway induced apoptosis of CLL cells [22], and inhibition of
Figure 3. IL-6 induces ROR1 promoter activity by activating Stat3. A. A schematic diagram of the ROR1 reporter constructs (left) that were
transfected into MM1 cells and maintained in the absence or presence of 20 ng/ml IL-6; their relative luciferase activity is also depicted. The right
panel depicts the means 6 standard deviation of the relative luciferase activity measured in four different experiments in which transfection
efficiency of the truncated ROR1 promoter constructs into MM1 cells was at least 40%. Construct ROR1 2195 and the upstream constructs exhibited
significant IL-6-induced luciferase activity. The schematic diagram in the left lower corner depicts four putative Stat3 binding sites. B. Co-transfection
efficiency of IL-6-stimulated MM1 cells previously transfected with the ROR +177, ROR1 2195, and ROR1 2360 truncated constructs. C. STAT3-siRNA
downregulated the luciferase activity of MM1 cells transfected with ROR1 2195 and ROR1 2360 but not ROR1 +177, suggesting that IL-6 induced
luciferase activity by activating Stat3. Student’s t test was used to determine whether the differences between luciferase activity values are significant.
D. EMSA using biotin-labeled and unlabeled probes of the four putative Stat3 binding sites shows that MM1 cell nuclear protein bound to the
biotinylated DNA probes 1 and 3 and that the addition of the corresponding cold (unlabeled) probes attenuated the binding of the hot (labeled)
probes. Binding to probe 1 is lighter than probe 3 because of unequal loading. E. Single nucleotide (T to G) mutation either at position 2133 or
position 2418 abrogates the IL-6-induced luciferase activity of ROR1 2834.
doi:10.1371/journal.pone.0011859.g003
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[30]. Wnts are capable of signaling through several pathways,
including the Wnt receptor Frizzled, which is reported to be
overexpressed in CLL [9,22], and the canonical b-catenin-
mediated pathway [31,32]. Remarkably, alternative splicing
causing silencing of E-cadherin, a negative regulator that binds
b-catenin and prevents its translocation to the nucleus [33], was
recently described in CLL cells [34].
Ror proteins have emerged as central regulators of Wnt
signaling [1]. ROR1 is overexpressed in CLL and, as confirmed
in our current study, its protein is present in unstimulated CLL
cells [8,9,10,11] and its downregulation enhances apoptosis. Stat3
is constitutively activated in CLL [14], and activated Stat3 binds
target gene promoters containing a GAS-like element [15]. Stat
dimers recognize 8- to 10-base-pair inverted repeat DNA elements
with a consensus sequence of 59-TT(N4–6)AA-39. Binding affinity
of an activated Stat dimmer to a target DNA sequence is
determined by variations in the nucleotide sequence [35] and by
cooperative dimer-dimer interactions mediated by NH2-terminal
amino acids [36,37]. Because sequence analysis revealed that the
Figure 4. IL-6-activated Stat3 binds to the ROR1 promoter and activates transcription in MM1 cells. A. ROR1 promoter biotinylated DNA
probe binds to nuclear protein of unstimulated or IL-6-stimulated MM1 cells. The addition of an unlabeled (cold) probe attenuated the binding of the
hot (biotin-labeled) probe. Similarly, anti-Stat3 (total Stat3) and anti-phosphotyrosine-Stat3 antibodies attenuated the binding of the hot probe,
suggesting that nuclear Stat3 protein bound the labeled ROR1 probe. B. ChIP demonstrates that anti-(total) Stat3 antibodies immunoprecipitated
ROR1, STAT3, and the Stat3-regulated genes c-Myc and p21. These genes were detected in MM1 cell nuclear extracts (Input) as well as in nuclear
protein immunoprecipitated with anti-Stat3 antibodies, particularly in IL-6-stimulated MM1 cells, suggesting that Stat3, known to bind Stat3-
regulated gene promoters, also binds the ROR1 promoter. C. qRT-PCR demonstrates that STAT3-siRNA downregulates the mRNA levels of ROR1,
STAT3, and the Stat3-regulated genes c-Myc, Cyclin D1, and p21. S18 mRNA (control) was not affected. D. Western blot analysis shows that STAT3-
siRNA, but not scrambled-siRNA or GAPDH, downregulates the protein levels of Stat3 and Ror1.
doi:10.1371/journal.pone.0011859.g004
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Stat3 binds to the ROR1 promoter and induces Ror1 protein
production in CLL cells.
That Stat3 activates ROR1 has not been previously reported.
To study this interaction, we used, as a Stat3-inducible model,
MM1 cells. Consistent with our previous study [16], we found that
IL-6 induced Stat3 phosphorylation in MM1 cells and, as we
assumed, upregulated Ror1 protein levels in a time- and dose-
dependent manner. In order to identify Stat3 binding sites in the
ROR1 promoter, we obtained genomic DNA from patients with
CLL and cloned the ROR1 promoter. We generated different-
length ROR1 promoter constructs, transfected them into MM1
Figure 5. CLL-cell constitutively activated Stat3 binds the ROR1 promoter at the previously identified Stat3 binding sites. A. EMSA,
performed using cells of CLL patients 8 and 9, demonstrates that CLL-cell nuclear protein binds the ROR1 biotinylated (labeled)-DNA probe. The cold
(unlabeled) probe attenuated the binding of the hot probe and a similar effect was obtained with anti-Stat3 and anti-phosphoserine-Stat3 antibodies.
IgG was used as control. These data suggest that Stat3 binds the ROR1 promoter in primary CLL cells. B. A schematic diagram showing the DNA
regions for which 59 and 39 primers were designed to generate DNA probes, as described in the Materials and Methods. Primer sets 1 through 4 were
designed to cover Stat3 putative binding sites (as shown in Fig. 3A), whereas primer set 5 covers a region lacking GAS-like elements (control). C. DNA
probes generated by primer sets 1 and 3 (generating DNA probes harboring the corresponding Stat3 binding sites), but not those generated by
primer sets 2, 4, or 5, bind nuclear protein of cells obtained from CLL patient 10, as assessed using ChIP. D. ChIP of nuclear protein from CLL cells of
patient 11 demonstrates that Stat3 co-immunoprecipitated with ROR1, STAT3, and the Stat3-regulated genes c-Myc and p21. The control gene RPL-
30, detected in whole-cell nuclear protein (Input), does not co-immunoprecipitate with Stat3.
doi:10.1371/journal.pone.0011859.g005
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induced activity with constructs upstream of ROR1 232. By using
siRNA, we confirmed that Stat3 activates ROR1 promoter
activity, and using EMSA we identified two Stat3 binding sites
in the ROR1 promoter. One site is located within the region from
2143 to 2114 and the other from 2429 to 2400. Remarkably,
MM1 cells transfected with ROR1 2666, which harbors the
2429 Stat3 binding site, exhibited relatively low luciferase activity
upon IL-6 stimulation, suggesting that a repressor(s) might be
present in this region. Transfection of MM1 cells with STAT3-
siRNA downregulated ROR1 mRNA and the protein levels of
both Stat3 and Ror1, confirming that Stat3 induces the expression
of ROR1 in MM1 cells.
ROR1 is overexpressed in various neoplasms, including
different subsets of B-cell acute lymphoblastic leukemia [38,39]
and the cervical carcinoma Hela cells. Similar to its role in
conferring a survival advantage to CLL cells [10,11], Ror1 was
identified as a potent survival kinase in Hela cells [40]. Therefore,
it is not surprising that we found that unstimulated B-lymphoid
MM1 cells express low levels of Ror1 and that IL-6 upregulated
Ror1 protein levels in these cells by activating Stat3. Constitutive
Stat3 phosphorylation has been found in several solid tumors and
hematologic malignancies [41,42,43,44], and it is likely that
ROR1 will be detected in these neoplasms as well.
Results obtained in unstimulated CLL cells were similar to
those in IL-6-stimulated MM1 cells. EMSA confirmed that Stat3
binds to the ROR1 promoter, probe sets designed for the regions
containing Stat3 putative binding sites determined that Stat3
binds to the ROR1 promoter at the same sites as in MM1 cells,
and anti-Stat3 antibodies pulled down STAT3, ROR1, and
Stat3-regulated gene DNA. Not all Stat3 putative binding sites
were examined. Therefore, it is possible that Stat3 binding sites
upstream of 2429 might be operative. STAT3-shRNA down-
regulated STAT3 and ROR1 mRNA and Stat3 and Ror1
protein levels, suggesting that constitutively phosphorylated Stat3
activates ROR1 in CLL.
The interaction between Stat3 and Wnt signaling in CLL is not
fully understood. Several investigators have reported that Stat3
induces Wnt5a expression [45,46,47]. Notably, Wnt5a binds to
Ror1 [11]. Thus, it is possible that Stat3 activates the Wnt
signaling pathway by inducing both ROR1 and Wnt5a expression
in CLL cells. However, other interactions between Stat3 and the
Wnt pathway exist in various cellular systems. In embryonic stem
cells, the Wnt/b-catenin pathway upregulates Stat3 mRNA [48],
and in thymocytes Wnt1 is overexpressed and induces serine
phosphorylation of Stat3 without affecting tyrosine phosophoryla-
tion [49], suggesting an autocrine interaction between Stat3 and
Wnt signaling. Whether a similar interaction exists in CLL
remains to be determined.
Figure 6. STAT3-shRNA downregulates ROR1 expression and
Ror1 protein levels and ROR1-siRNA downregulates ROR1 and
induces the apoptosis. A. A 67% infection efficiency of retroviral
STAT3-shRNA into CLL cells from a patient was obtained. B. qRT-PCR of
these CLL cells demonstrates that STAT3-shRNA downregulated mRNA
levels of ROR1, STAT3, and the Stat3-regulated genes Bcl2, Bcl-XL, Cyclin
D1, c-Myc, p21, and Pim1. S18 mRNA (control) was not affected. C.
STAT3-shRNA, but not the empty vector, downregulates Stat3 and Ror1
protein levels. D. Left upper panel: ROR1-siRNA downregulated ROR1
mRNA levels. qRT-PCR results are depicted. GAPDH-siRNA was used as
control. Right upper corner: ROR1-siRNA, but not GAPDH-siRNA,
downregulates Ror1 protein levels. Lower panel: Knock-down of ROR1
induces apoptosis. ROR1-siRNA increased CLL cell apoptosis rate of
from 19% (GAPDH-siRNA control) to 39.9% (ROR1-siRNA).
doi:10.1371/journal.pone.0011859.g006
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B-cell CLL cell fractionation
PB cells were obtained from patients with CLL who were
treated at The University of Texas M. D. Anderson Cancer
Center Leukemia Clinic after Institutional Review Board approval
and a written patient informed consent were obtained. The clinical
characteristics of the patients whose PB samples were used in the
study are presented in Table S1. To isolate low-density cells, PB
cells were fractionated using Ficoll Hypaque 1077 (Sigma-Aldrich,
St. Louis, MO). More than 90% of the PB lymphocytes obtained
from these patients were CD19+/CD5+.
Cell culture
Fractionated CLL cells were maintained in DMEM (Sigma-
Aldrich) supplemented with 10% FBS (Hyclone, Logan, UT).
The human multiple myeloma MM1 and the human embryonic
kidney (HEK) 293FT cell lines were obtained from the American
Type Culture Collection (Rockville, MD). MM1 cells were
maintained in RPMI 1640 (Sigma-Aldrich), and 293FT cells were
maintained in DMEM supplemented with 10% FBS, both in a
humidified atmosphere of 5% CO2 at 37uC. Prior to analysis,
MM1 cells were incubated with either recombinant human
IL-6 (BioSource International, Camarillo, CA) or tissue culture
medium.
Western blot analysis
Western immunoblotting was performed as previously de-
scribed [50]. Briefly, cell pellets were lysed in ice-cold Ripa buffer
containing 1 mM sodium orthovanadate, 10 mM sodium fluo-
ride, 100 mM EDTA, 5 mM b-glycerol phosphate, 1 mg/ml
aprotinin, 0.4 mM benzamidine, 1 mg/ml antipain, 1 mM
phenylmethylsulphonyl fluoride (PMSF), 1 mg/ml leupeptin,
and 1 mg/ml soybean trypsin inhibitor. The lysed cell pellets
were incubated on ice for 5 minutes and vortexed for 1 minute.
Then, cell debris was eliminated by centrifugation at 14,000 rpm
for 15 minutes, supernatants were harvested, and the protein
concentration was determined using the Micro BCA protein
assay reagent kit (Thermo Scientific, Pierce, Rockford, IL).
Supernatant proteins were denatured by boiling for 5 minutes in
sodium dodecyl sulfate (SDS) loading buffer, separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), and transferred
to a nitrocellulose membrane. Following transfer, equal loading
was verified by Ponceau S staining. The membranes were
blocked with 5% skim milk in Tris-buffered saline and incubated
with the following antibodies: monoclonal mouse anti-human
Stat3 (BD Biosciences, Palo Alto, CA; Cell Signaling Technology,
Beverly, MA); monoclonal mouse anti-human phosphotyrosine
Stat3, polyclonal rabbit anti-human phosphoserine Stat3, poly-
clonal rabbit anti-human Ror1 (Cell Signaling Technology), and
monoclonal mouse anti-human b-actin (Sigma-Aldrich). After
binding with horseradish peroxidase-conjugated secondary anti-
bodies, blots were visualized with an ECL detection system (GE
Healthcare, Amersham, Buckinghamshire, UK), and densitom-
etry analysis was performed using the Epson Expression 1680
scanner (Epson America, Inc., Long Beach, CA). Densitometry
results were normalized by dividing the numerical value of each
sample signal by the numerical value of the signal from the
corresponding loading control. In some experiments, the
membranes were stripped by incubation with stripping buffer
(62.5 mM Tris-HCl, pH=6.7, 2% SDS, 100 mM b-mercapto-
ethanol) for 30 minutes at 50uC, washed, and re-probed with an
antibody.
Generation of luciferase reporter plasmids and site-
specific mutagenesis
A 1.5-kb fragment of the human ROR1 promoter was
generated by PCR using, as a template, genomic DNA isolated
from PB low-density cells that were obtained from two patients
with CLL (patients 13 and 14, Table S1). The DNA was purified
by using the Wizard DNA Purification Kit (Promega, Madison,
WI). Human ROR1 promoter PCR primers were designed in
accordance with the sequence of the ROR1 59-flanking region
(Ensembl Resource, www.ensembl.org; Fig. 1). The ROR1
promoter PCR primers included a forward primer starting at bp
21173 (relative to the start of the first exon), a reverse primer
starting at bp +349, and several smaller forward primers, as
depicted in Table S2. The amplified fragments were attached to
BglII- and SacI-digestion sites of the pGL4-basic vector (Promega)
containing a luciferase reporter gene. The pGL4 vectors harboring
ligation products were introduced into One Shot TOP10
chemically competent E. coli (Invitrogen, San Diego, CA). Fifty
microliters of each transformed-bacteria batch was spread onto
agar plates containing ampicillin (Invitrogen) and incubated
overnight at 37uC. Single ampicillin-resistant colonies were
microaspirated and analyzed following restriction enzyme diges-
tion. The sequences of all constructs were verified by automated
sequencing (Seqwright, Houston, TX).
The pGL4 basic reporter driven by 834-bp human Ror1
promoter was used for site-specific mutagenesis. Mutants at
positions 2133 and 2418 (TT mutated to TG) were generated
by using the QuickChange Site-Directed Mutagenesis kit (Strata-
gene) and confirmed by sequencing.
Transfection of MM1 cells and luciferase assay
MM1 cells were transfected by electroporation with the Gene
Pulser Xcell Electroporation System (Bio-Rad, Hercules, CA,
USA). A total of 5610
6 cells, suspended in 0.2 ml serum-free
OPTI-MEMI medium (Invitrogen, San Diego, CA, USA), were
transfected with 2 mg of each of the specific reporter constructs.
Luciferase activity was assessed 48 hours after transfection by
using the Dual-Luciferase Reporter Assay System (Promega) and
the SIRIUS luminometer V3.1 (Berthold Detection Systems,
Pforzheim, Germany). The luciferase activity of each of the human
ROR1 promoter constructs was determined by calculating the
constructs’ luciferase activity relative to the activity of the Renilla
luciferase produced by the pRL-SV40 control vector and
reporting the mean results of at least three separate experiments.
RNA purification and qRT-PCR
RNAwas isolated using anRNeasy purification procedure(Qiagen,
Inc., Valencia, CA). RNA quality and concentration were analyzed
with a NanoDrop spectrophotometer (ND-1000; NanoDrop Tech-
nologies, Wilmington, Delaware). Five hundred nanograms of total
RNA was used in one-step qRT-PCR (Applied Biosystems, Foster
City, CA), with the sequence detection system ABI Prism 7700
(Applied Biosystems) using TaqMan gene expression assay for ROR1
(Hs 00178178-M1), STAT3, Bcl2, Bcl-XL,c - M y c ,P i m 1 ,p 2 1
(WAF1), Cyclin D1, and S18 according to the manufacturer’s
instructions. Samples were run in triplicate, and relative quantification
was performed by using the comparative CT method [14].
Electrophoretic mobility shift assay (EMSA)
Non-denatured cellular nuclear extracts were prepared using
the NE-PER extraction kit (Thermo Scientific, Pierce). Two
micrograms of nuclear protein extracts were incubated with
biotin-labeled ROR1 promoter DNA probes in binding buffer for
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(The Woodlands, TX). The sequences of the probes used are as
follows: probe 1, 2143 CCG CGA CCG CTT TCT GCG AAG
TCG GGG AGG 2114; probe 2, 230 GGC TGG AGA GTT
GGT GGA AAG TGA CAA GTT-1; probe 3, 2429 TCT CTC
AAC TCT TGG GTC CAA GAA GAA AGC 2400; and probe
4, 21053 TGA CTC TTT TTA GTG TCA ATG GAG GAT
TTG 21024. Following incubation, the samples were separated
on a 5% polyacrylamide gel in Tris-borate EDTA, transferred
onto a nylon membrane, and fixed on the membrane by
ultraviolet cross-linking. The biotin-labeled probe was detected
with strepavidin-horseradish peroxidase (Gel–Shift Kit; Panomics,
Fremont, CA). The competition control consisted of up to 7-fold
excess unlabeled cold probe combined with biotin-labeled probes.
To determine the effect of antibodies on protein-DNA binding,
1 mg monoclonal mouse anti-human Stat3 (BD Bioscience; Cell
Signaling Technology) or mouse anti-human phosphoserine Stat3
(Cell Signaling Technology) antibody was incubated with the
nuclear extracts for 30 minutes on ice prior to the addition of the
biotin-labeled DNA probe. The isotypic controls consisted of
mouse immunoglobulin (Ig) G1 (BD Bioscience).
ChIP assay
The ChIP assay was performed using a SimpleChIP Enzymatic
Chromatin IP Kit (Cell Signaling Technology) in accordance with
the manufacturer’s instructions. Briefly, cells were cross-linked
with 1% formaldehyde for 10 minutes at room temperature and
then harvested and incubated on ice for 10 minutes in lysis buffer.
Nuclei were pelleted and digested by micrococcal nuclease.
Following sonication and centrifugation, sheared chromatin was
incubated with anti-STAT3 or rabbit serum (negative control)
overnight at 4uC. Then, protein G beads were added and the
chromatin was incubated for 2 hours in rotation. An aliquot of
chromatin that was not incubated with an antibody was used as
the input control sample. Antibody-bound protein/DNA com-
plexes were eluted and subjected to PCR analysis. The primers to
amplify the human STAT3 promoter were F: 59-CCG AAC GAG
CTG GCC TTT CAT-3 and R: 59-GGA TTG GCT GAA GGG
GCT GTA-3, which generated an 86-bp product; primers to
amplify the WAF/p21 promoter were F: 59-TTG TGC CAC
TGC TGA CTT TGT C-3 and R: 59-CCT CAC ATC CTC
CTT CTT CAG GCT-3, which generated a 303-bp product; and
primers to amplify the c-Myc promoter were F: 59-TGA GTA
TAA AAG CCG GTT TTC-3 and R: 59-AGT AAT TCC AGC
GAG AGG CAG-3, which generated a 63-bp product. The
primer sets used to amplify ROR1 promoter putative Stat3
binding sites were as follows: set 1, 2195 TTT GAG GAG TGT
GGG GGA GGG and GTT GAG AGG CTG CAG CAG
AGG285; set 2, 2105 GTT GAG AGG CTG CAG CAG AGG
and GGC TGG AGA GTT GGT GGA AAG210; set 3, 2509
GGC AGT ACA GAT GAC ATT GAA and TTG GGT CCA
AGA AGA AAG CAA2400; set 4, 21173 TGG CTA CCC CAT
GTC TGT GAG and GGA GGA TTT GTG AGC AAA
TGC21013; and set 5, 1595 CAT TCG GAA GAC AAA AAC
ACC and GGC AGT ACA GAT GAC ATT GAA2489. The
human RPL30 gene primers were provided by Cell Signaling
Technology. PCR products were resolved on 1.8% agarose gels.
Stat3 and ROR1 siRNA transfection
MM1 and CLL cells were transfected by electroporation as
described above. Knockdown of endogenous Stat3 was performed
using the pre-designed siRNA and scrambled siRNA from
Ambion Applied Biosystems. The siRNA sequences used to target
exon 14 and 15 of the human STAT3 gene were antisense 59-
GGG AAG CAU CAC AAU UGG Ctc-39 and sense 59-GCC
AAU UGU GAU GCU UCC Ctt-39. SiRNA at a final
concentration of 50 nM was also co-transfected with luciferase
reporter plasmids into MM1 cells. Transfectants were maintained
in the complete medium for 48 hours before being used in the
luciferase activity assay and in qRT-PCR analysis. The siRNA
sequences used to target the human ROR1 gene were antisense
59-AGA CUU AAA GUU UUC AUC CAA-39 and sense 59-GGA
UGA AAA CUU UAA GUC UTT. 30nM of siRNA was mixed
with siPORT NeoFX Transfection Agent (Ambion) and transfected
by electroporation into CLL cells. Transfected cells were
maintained in co-culture with mesenchymal stroma cells and
qRT-PCR of ROR1 was performed at 72 hours after transfection.
Preparation of lentivirus STAT3-shRNA and infection of
cells
HEK 293FT cells were co-transfected with GFP-lentivirus STAT3
shRNA or GFP-lentivirus empty vector and the packaging vectors
pCMVdR8.2 and pMDG (generously provided by Dr. G. Inghirami,
Torino, Italy) using the superfect transfection reagent (Qiagen, Inc.).
293FT cellculture mediumwaschanged after16 hoursand collected
after 48 hours. The culture medium was filtered through a 45-mm
syringe filter to remove floating cells, the lentivirus was concentrated
by filtration through an Amicon Ultra centrifugal filter device
(Milipore, Billerica, MA), and the concentrated supernatant was used
to infect CLL cells. CLL cells (5610
6/ml) were incubated in 6-well
plates (Becton Dickinson, Franklin Lakes, NJ) in 2 ml DMEM
supplemented with 10% FBS and transfected with 100 mlo fv i r a l
supernatant. Polybrene (10 ng/ml) was added to the viral superna-
tant at a ratio of 1:1000 (v/v). Transfection efficiency was measured
after 48 hours and was found to range between 45% and 60%
(calculated on the basisof theratio ofpropidiumiodide(PI)-negative/
GFP-positive cells). RNA was isolated and prepared for qRT-PCR
analysis as previously described [14].
Supporting Information
Table S1 Patient characteristics.
Found at: doi:10.1371/journal.pone.0011859.s001 (0.05 MB
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